Mark A. Goldsmith - 17 Mar 2022 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
President and Chief Executive Officer, Director
Signature
/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith
Issuer symbol
RVMD
Transactions as of
17 Mar 2022
Net transactions value
-$19,042
Form type
4
Filing time
21 Mar 2022, 20:02:01 UTC
Previous filing
03 Mar 2022
Next filing
10 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Sale $19,042 -1,023 -0.55% $18.61 185,599 17 Mar 2022 Direct F4, F5, F6
holding RVMD Common Stock 37,032 17 Mar 2022 Trust F1
holding RVMD Common Stock 37,032 17 Mar 2022 Trust F2
holding RVMD Common Stock 266,506 17 Mar 2022 Trust F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Held by Jonathan Henry Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.
F2 Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.
F3 Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
F4 Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.
F5 This transaction was executed in multiple trades in prices ranging from $18.1186 to $18.62, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F6 Includes 140,000 RSUs.

Remarks:

President and Chief Executive Officer